

1  
2 **Reevaluation of Seroprevalence using a Semi-quantitative Anti-spike IgG in Health Care**  
3 **workers at an Academic Medical Center in Boston, Massachusetts**

4  
5 Manisha Cole<sup>1,2</sup>, Elizabeth R. Duffy<sup>2</sup>, Jordyn N Osterland<sup>1,2</sup>, Susan Gawel<sup>3</sup>, Lei Ye<sup>3</sup>, Kyle de la  
6 Cena<sup>2</sup>, Elizabeth J. Ragan<sup>4</sup>, Sarah E. Weber<sup>4</sup>, Elissa M- Schechter-  
7 Perkins<sup>5</sup>, Tara C. Bouton<sup>4</sup>, Karen R. Jacobson<sup>4</sup>, Chris Andry<sup>1,2</sup>, Yachana Kataria<sup>1,2\*</sup>

8  
9 <sup>1</sup>Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, MA

10 <sup>2</sup>Department of Pathology and Laboratory Medicine, Boston University School of Medicine,  
11 Boston, MA

12 <sup>3</sup>Abbott Laboratories, Department of Biostatistics

13 <sup>4</sup>Section of Infectious Diseases, Boston Medical Center, Boston, MA

14 <sup>5</sup>Department of Emergency Medicine, Boston University School of Medicine / Boston  
15 Medical Center, Boston, MA

16  
17 **Running Title:** SARS-CoV-2 IgG Semi-Quantitative Assay

18  
19 **Conflict-of-interest disclosure**

20 The authors declare no competing financial interests.

21  
22 **Corresponding Author**

23 Yachana Kataria, PhD, DABCC

24 Medical Director, Clinical Chemistry

25 Department of Pathology and Lab Medicine

26 670 Albany St.

27 Boston, MA 02118

28 Tel: 617-414-3727

29 Email: [Yachana.Kataria@bmc.org](mailto:Yachana.Kataria@bmc.org)

30  
31  
32  
33  
34 **Abstract (250 words)**

35  
36 **Background:** Accurate measurement of antibodies is a necessary tool for assessing exposure  
37 to SARS-CoV-2 and facilitating understanding of the role of antibodies in immunity. Most assays  
38 are qualitative in nature and employ a threshold to determine presence of antibodies. Semi-  
39 quantitative assays are now available. Here we evaluate the semi-quantitative SARS-CoV-2 IgG  
40 II (anti-spike (S)) assay. We aim to reassess the seroprevalence using anti- S assay and  
41 subsequently compare it to the previously measured IgG (anti-nucleoprotein (N)) in health care  
42 workers at an academic medical center in Boston.

43

44 **Methods:** 1743 serum samples from HCWs at Boston Medical Center were analyzed for SARS-  
45 CoV-2 anti-S IgG and IgM using the Abbott SARS-CoV-2 IgG II and Abbott AdviseDx SARS-  
46 CoV-2 IgM assay, respectively. Precision, linearity, positive and negative concordance with prior  
47 RT-PCR test were evaluated for anti-S IgG. Seroprevalence and its association with  
48 demographics variables was also assessed.

49

50 **Results:** Linearity and precision results were clinically acceptable. The positive and negative  
51 concordance for anti-S IgG with RT-PCR was 88.2% (95% CI: 79.4% - 94.2%) and 97.43%  
52 (95% CI: 95.2% - 98.8%), respectively. Overall, 126 (7.2%) of 1,743 participants were positive  
53 by anti-S IgG. Among the 1302 participants with no prior RT-PCR, 40 (3.1%) were positive for  
54 anti-S IgG antibody. The original agreement in this population with the qualitative, anti-N IgG  
55 assay was 70.6%. Upon optimizing the threshold from 1.4 to 0.49 S/CO of the anti-N IgG assay,  
56 the positive agreement of the assay increases to 84.7%.

57

58 **Conclusion:** The anti-S IgG assay demonstrated reproducible and reliable measurements. This  
59 study highlights the presence of asymptomatic transmission among individuals with no prior  
60 history of positive RT-PCR. It also highlights the need for optimizing thresholds of the qualitative  
61 SARS-CoV-2 IgG assay for better agreement between assays by the same vendor.

62

63

64

65

66

67

68

## 69 **Introduction**

70 Coronavirus disease 2019 (COVID-19) is the disease caused by the novel severe acute  
71 respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes fever, cough, shortness of  
72 breath, and fatigue that can quickly become life threatening (1-3). SARS-CoV-2 RNA testing  
73 alone, in the absence of serological testing, is not sufficient to assess population-level viral  
74 transmission and pathogen exposure and the public health burden of the pandemic (4). The  
75 transient nature of RNA testing makes it an inaccurate metric to assess viral transmission at a  
76 population level. Accurate measurement of antibodies can facilitate understanding the role of  
77 antibodies in immunity elicited by both natural and vaccine response (5, 6). Ongoing studies are  
78 investigating the durability of antibodies against SARS-CoV-2 and examining what levels confer  
79 protective immunity against severe disease and/or reinfection (6-9).

80

81 There has been a rapid increase in serological assay availability in the United States via  
82 Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA)(4, 10).  
83 These assays are designed to detect different immunoglobulin classes (IgM, IgG, IgA) or total  
84 antibodies to various epitopes of SARS-CoV-2. SAR-CoV-2 epitopes include the spike (S) or  
85 nucleocapsid (N) proteins. Most currently approved assays are qualitative in nature and employ  
86 a threshold to determine the presence of antibodies. Semi-quantitative assays are now  
87 available. To date, there are over 15 semi-quantitative assays approved for clinical testing in the  
88 United States including Roche Elecsys Anti-SARS-CoV-2 S, Phadia, Beckman Coulter, Inc.  
89 Access SARS-CoV-2 IgG II, AB EliA SARS-CoV-2-Sp1 IgG Test Phadia, Dimension EXL  
90 SARSCoV2 IgG, and Quanterix Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test  
91 among others (11). However, it remains unclear if the pre-defined threshold for current  
92 qualitative and semi-quantitative assays is appropriately set (4, 12). It is also unclear whether  
93 these SARS-CoV-2 serological assays are comparable which prohibits assessment of durability  
94 and correlation with protection to help inform public health policies (4, 13).

95  
96 We previously assessed seroprevalence among health care workers at an  
97 (11)(11)(11)academic medical center in Boston, Massachusetts, USA using the qualitative  
98 assay SARS-CoV-2 IgG (anti-nucleoprotein (N)) assay (11). Seroprevalence studies can assist  
99 in detecting asymptomatic and symptomatic infection and provide a cumulative prevalence  
100 estimate. Abbott Laboratories has now been issued an EUA for its anti-spike quantitative SARS-  
101 CoV-2 IgG II (anti-S IgG) and IgM (anti-S IgM) assay (6). In this study, we aim to reevaluate the  
102 seroprevalence in health care worker (HCW) population using the anti-S IgG assay and  
103 compare it to the anti-N IgG assay.

104

105

106

107

## 108 [Methods](#)

### 109 **Study Design & Participants**

110 Baseline samples were obtained from an ongoing longitudinal cohort assessing COVID-19  
111 serological status among HCW's at Boston Medical Center (BMC). In brief, participants were  
112 adult BMC employees who worked on campus during the first COVID-19 surge in Boston, MA  
113 (March 13th-May 31st, 2020). Baseline serum samples were obtained between July 13th-26th,  
114 2020 (n= 1,743) and had been previously analyzed for anti-N IgG antibody status (Abbott  
115 Laboratories, Abbott Park, IL). Participants completed extensive questionnaire data on  
116 demographics (age, gender, race, ethnicity) between January 1<sup>st</sup> – My 31<sup>st</sup>, 2020. Prior RT-  
117 PCR COVID-19 test results completed at BMC during the same period, were confirmed in  
118 the electronic medical record. This project was approved by the Institutional Review Board at  
119 Boston University Medical Center (BUMC).

120  
121 For the current investigation, we analyzed serum samples for SARS-CoV-2 anti-S IgG & IgM (n  
122 = 1,743). These assays were performed by the clinical pathology laboratory at BMC on the  
123 Abbott Architect i2000 Instrument (Abbott Laboratories, Abbott Park, IL). Assays were run per  
124 the manufacturer's instructions. For both assays, aliquots of serum samples (~500 ul) were  
125 thawed for either 24 hours at 4°C or 2 hours at room temperature prior to being analyzed.

126

127

128

### 129 **SARS-CoV-2 IgM Assay (Qualitative)**

130 The [AdviseDx SARS-CoV-2 IgM \(anti-S IgM\) assay](#) is a chemiluminescent microparticle  
131 immunoassay (CMIA) for the qualitative detection of IgM antibody in human serum against the  
132 SARS-CoV-2 spike protein.

133

134 In this automated assays, participant serum, paramagnetic particles coated with SARS-CoV-2  
135 antigen, and an assay diluent are incubated together during which the antibodies present in the  
136 serum sample bind to the antigen. The resulting luminescence will be read and resulted as a  
137 relative light unit (RLU). Both assays rely on an assay-specific calibrator to report a ratio of  
138 specimen RLU to calibrator RLU. Interpretation of positivity is determined by an index  
139 value above a predefined threshold (8, 9).

140  
141 IgM samples were interpreted as positive (index value  $\geq 1.00$ ) or negative (index value  $< 1.00$ ).  
142 Both qualitative and quantitative results were used in the analysis.

143  
144 **Anti-S IgG Assay (Semi-Quantitative)**

145 Aliquots of serum samples (~500 ul) were thawed for either 24 hours at 4°C or 2 hours at room  
146 temperature prior to being analyzed.

147  
148 The Abbott ARCHITECT SARS-CoV-2 IgG II assay is a semi-quantitative assay that detects  
149 IgG antibodies to the receptor binding domain (RBD) of the S1 subunit of the spike protein of  
150 SARS-CoV-2 in human plasma. It is a two-step indirect CMIA.

151  
152 The assay utilizes magnetic microparticles coated with RBD recombinant protein. The mixture is  
153 incubated and then washed prior to the addition of an anti-human-IgG antibody conjugated to  
154 acridinium. The recorder molecule is incubated prior to a second wash and followed by addition  
155 of a triggering solution that generates luminescence. The light is captured and counted to give  
156 an RLU. The RLU's are read of a six-point calibration curve stored on the instrument generating  
157 an AU/mL (arbitrary units/milliliter) value. The assay is standardized to a monoclonal antibody  
158 concentration (14). Samples were interpreted as positive when  $\geq 50.0$  AU/mL or negative  
159 when  $<50.0$  AU/mL. Both qualitative and quantitative results were used in the analysis.

160

### 161 **Precision SARS-CoV-2 IgM & Anti-S IgG**

162 Precision studies were performed on quality control (QC) material as supplied by Abbott

163 Diagnostics. IgM has two levels of QC: negative and positive. Anti-S IgG has three levels of QC:

164 negative, low positive, and high positive. Intra-day precision was assessed by analyzing 20

165 replicates of each level of QC on the same day. Inter-day precision was assessed by analyzing

166 QC for 20 days.

167

### 168 **Linearity Anti-S IgG Studies**

169 The analytical measuring range of anti-S IgG is 22.0 - 25,000 AU/mL. The suggested

170 manufacturer dilution is 1:2, extending the measuring upper limit to 50,000 AU/mL.

171 Dilution studies were carried out using two participants that had elevated serum samples.

172 Although the EUA approved upper linearity is 25,000 AU/mL, reagent was received prior to EUA

173 approval and was reported to be 50,000 AU/mL at the time of these analyses. These samples

174 were diluted serially with negative control. A total of 7 levels were tested in triplicates on the

175 Abbott Architect i2000 instrument.

176

### 177 **Statistical Analysis**

178 Questionnaire data were collected and managed in REDCap electronic data capture tools

179 hosted at Boston University, CTSI 1UL1TR001430 (15, 16). Imprecision was assessed by

180 measuring mean, standard deviation (SD), and coefficient of variation (CV) for inter and intra-

181 day precision. Anti-S IgG data were log transformed (base 2) for analysis and ease of

182 visualization.

183

184 Categorical data are presented as counts. We tested the association between anti-S IgG with  
185 sex, race, and gender using a Fisher's Exact Test analysis. Missing data of less than 5% was  
186 excluded from analysis.

187  
188 Positive and negative concordance of anti-S IgG was calculated using molecular testing (RT-  
189 PCR) as the gold standard among participants with a prior RT-PCR test result. Comparison  
190 between assays was assessed by McNemar's chi-squared test. Receiver operating  
191 characteristics (ROC) curve was used to assess assay thresholds and define trade-offs in assay  
192 sensitivity and specificity using to RT-PCR test as the gold standard.

193  
194 A P-value of  $< 0.05$  was considered statistically significant, and all tests were two-sided.  
195 Analyses were performed in R Version R-3.5.3 (R Foundation for Statistical Computing). Select  
196 figures were produced by GraphPad Prism version (9.0.2) by GraphPad Software (San Diego,  
197 USA).

198

## 199 Results

200

### 201 Precision

202 IgM negative and positive control exhibited an intra-day CV of 16.5%, and 2.2%, respectively.  
203 IgM negative and positive control exhibited an inter-day CV of 21.3%, and 1.9%, respectively  
204 **(Supplementary Table 1).**

205

206 Anti-S IgG negative, low positive, and high positive control exhibited an intra-day CV of 23.9%,  
207 3.3%, and 2.9%, respectively. Anti-S IgG negative, low positive, and high  
208 positive control exhibited an inter-day CV of 16.6%, 2.4%, and 2.4%, respectively  
209 **(Supplementary Table 1).**



210

## 211 **Anti-S IgG Linearity**

212 Linearity data is shown in **Figure 1**. **Figure 1a** displays a participant result with greater than the  
213 analytical measuring range (46,820 AU/mL) and shows an acceptable linear response with a r-  
214 squared value of 0.99. Similarly, **Figure 1b** displays a participant result that had an original anti-  
215 S IgG level of 11,711.60 AU/mL with acceptable linearity with a r-squared value of 0.99, though  
216 not at the upper end of the analytical measuring range.

217

## 218 **Figure 1 – Linearity of Anti-S IgG**

219

220 The data suggests that the difference between expected and measured is within the 95% CI.  
221 Significant percentage differences are observed on the lower end of the analytical measuring  
222 range (**Supplementary Figure 1**).

223

## 224 **Seroprevalence**

225 **Table 1** shows demographics in relation to anti-S IgG status (n = 1,743). Overall, 126 of 1,743  
226 (7.23%) participants were anti-S IgG positive. Participants who were female, Hispanic, or Black  
227 were more likely to be seropositive, but these findings did not reach statistical significance.  
228 Obese participants were two times more likely to be seropositive for anti-S IgG [RR: 2.04 (95%  
229 CI: 1.40, 2.99)]. Among all the participants, anti-S IgG levels were not associated with age, race,  
230 or gender (**Figure 2a-c**).

231

## 232 **Figure 2 – Anti-S IgG by demographics - a). Age b). Gender c). Race**

233

234 441 of 1743 participants had a history of RT-PCR test. 47 of 85 RT-PCR  
235 confirmed positive individuals were also seropositive by IgM corresponding to a positive  
236 concordance of 55.3% (95% CI: 44.1% - 66.1%). 343 of 350 RT-PCR confirmed

237 negative participants were seronegative by IgM corresponding to a negative concordance of  
238 98.0% (95% CI: 95.9% - 99.2%) (**Supplementary Table 2**). Of the remaining six participants  
239 with indeterminate RT-PCR results, two had detectable IgM antibody.

240  
241 75 of the 85 RT-PCR confirmed positive participants were also seropositive by anti-S IgG  
242 corresponding to a positive concordance of 88.2% (95% CI: 79.4% - 94.2%). 341 of 350 RT-  
243 PCR confirmed negative participants were seronegative by anti-S IgG corresponding to a  
244 negative concordance of 97.43% (95% CI: 95.2% - 98.8%) (**Table 2**). A total of 1302  
245 participants had no prior RT-PCR test and of these participants, 40 (3.1%) were positive by anti-  
246 S IgG. Distribution of the anti-S IgG levels by RT-PCR test result is shown in **Figure 3**. Among  
247 the individuals with a prior RT-PCR, there is a statistically significant difference among the anti-  
248 S IgG levels by RT-PCR test result ( $p < 0.001$ ).

249  
250 **Figure 3** – Anti-S IgG distribution by SARS-CoV-2 RT-PCR status  
251

252 A total of 270 of the 441 individuals with a prior RT-PCR test had a recorded date of RT-PCR.  
253 **Figure 4** displays anti-S IgG level distribution since RT-PCR date. There was no statistical  
254 difference between anti-S levels in individuals less than 120 days after positive RT-PCR test  
255 result ( $p = 0.16$ ) (**Supplementary Figure 2**). Anti-S IgG antibodies in RT-PCR confirmed  
256 individuals remained elevated over 120 days post infection.

257 **Figure 4** – Anti-S IgG distribution days post SARS-CoV-2 RT-PCR result

258

### 259 **Agreement between Anti-N IgG vs. Anti-S IgG Status**

260 Overall agreement between the two assays in this population was found to be 97.5% (95% CI:  
261 96.7% - 98.2%). Of note, the positive agreement was 70.6% (95% CI: 61.8% - 78.4%), whereas

262 the negative agreement was 99.6% (95% CI: 99.2% - 99.9%). These two tests were found to be  
263 statistically different ( $p < 0.001$ ).

264  
265 A total of 37 participants had detectable anti-S IgG but were negative by anti-N IgG (**Table**  
266 **3a**). Of these, 11 participants had a positive RT-PCR, 3 participants had a negative RT-PCR,  
267 1 participant had an indeterminate RT-PCR, and 22 were not tested. Of interest, 6 participants  
268 had detectable anti-N IgG results but were negative by anti-S IgG.

269 **Table 3 – Anti-N IgG vs. Anti-S IgG Agreement**

270  
271 **Assay Threshold Optimization**  
272 ROC curve analysis showed that the SARS-CoV-2 IgG qualitative had optimal sensitivity and  
273 specificity target e.g., adjusting threshold to 0.49 S/CO would result in a sensitivity of 84.7% and  
274 specificity of at least 96.9% (**Supplementary Figure 3**).

275  
276 As such, changing the threshold of positivity for the anti-N IgG assay from 1.4 to 0.49 S/CO ratio  
277 increased the positive agreement between anti-N IgG & anti-S IgG from 70.6% to 86.5% (95%  
278 CI: 79.3% - 91.9%). However, it did not appreciably affect the negative agreement, from 99.6%  
279 to 98.7% (95% CI: 98.0% - 99.2%) (**Table 3b**). Upon threshold modification, the two anti-N IgG  
280 vs. anti-S IgG were found to be statistically aligned.

281

282

283 **Discussion**

284

285 This study reevaluates the seroprevalence in HCWs using a semi-quantitative anti-S IgG assay.

286 It also compares the findings to the anti-N IgG in the same population. We report an overall

287 seroprevalence of 7.2%. Among participants with a negative RT-PCR 2.5% of participants had  
288 detectable anti-S IgG antibody. We also observed a seroprevalence of 3.1% among participants  
289 with no prior RT-PCR. Our results demonstrate that the anti-S & anti-N IgG assays were  
290 statistically different. Upon lowering the anti-N IgG assay threshold, overall agreement between  
291 the two assays improved. Taken together, these results support the clinical utility of anti-S IgG  
292 assay and highlight the presence of COVID-19 infection among individuals with a negative or no  
293 prior RT-PCR.

294  
295 The anti-S IgG shows acceptable intra- and inter-day precision. The precision for the negative  
296 control is expected to be high due to a lower numerical value and small variations observed  
297 artificially increase the CV. Our results depict acceptable linearity up to 50,000 AU/mL which  
298 exceeds upper limit stated in the package insert. It is currently unclear what titer levels confer  
299 SARS-CoV-2 immunity but our data suggest that such elevated levels are not rare among the  
300 participants.

301  
302 Our results indicate less than ideal positive concordance for anti-S IgG vs. RT-PCR testing  
303 which is inconsistent with the manufacturer claims. Further investigation of the discordant  
304 samples (n=10) unveil that these participants did not have detectable anti-N IgG, or IgM  
305 antibody. These findings can possibly be explained by mild symptoms and/or disease. Literature  
306 suggests that the intensity and longevity of antibody response is associated with disease  
307 severity (17-19). The negative concordance of the SARS-CoV-2 assay was robust and  
308 consistent with the manufacturer claims.

309  
310 Neither SARS-CoV-2 anti-N nor anti-S IgG assays find an association with sex, race, smoking  
311 status. However, the seroprevalence determined by anti-S IgG assay was higher (7.2%) relative  
312 to the anti-N IgG assay (5.5%) (8). The observed seroprevalence at a regional Boston area

313 hospital was comparable to ours (20). Whereas others in the larger Boston region have reported  
314 a seroprevalence range between 14% to 25% (21). Seroprevalence can vary between sampling  
315 times and geographic regions. Among participants that had no prior RT-PCR test, 40  
316 participants had detectable anti-S IgG antibody and 23 participants had detectable anti-N IgG  
317 antibody. As such, 17 additional individuals were identified to have IgG antibodies. This  
318 suggests higher sensitivity of the anti-S IgG assay which is corroborated by others (22).  
319 Alternatively, it may be attributable to a shorter half-life of anti-N IgG antibody (7).

320  
321 These individuals pose a risk of asymptomatic viral transmission. Studies suggest that  
322 asymptomatic individuals are a source of transmission even after being vaccinated (23-25).  
323 Ultimately, RT-PCR testing is limited by the brief infectious window during which viral detection  
324 is possible. Detectable viral loads during infection via RT-PCR can vary by several factors such  
325 as patient medical history, immune response, and medications, whereas antibody  
326 measurements can detect exposure to virus for longer periods of time (26, 27). Our data  
327 suggests that participants in the study had elevated anti-S IgG for at least 120 days after RT-  
328 PCR tests. The longevity of detectable antibody remains unclear especially in less severe  
329 infections.

330  
331 The qualitative nature of the anti-N IgG assay enabled us to optimize the pre-set threshold.  
332 Upon changing the anti-N IgG threshold, the assays exhibit better agreement with anti-S IgG. 20  
333 of the 37 discordant participant samples became concordant. The remainder (14/17) discordant  
334 participants did not have a prior RT-PCR test, or a robust anti-N IgG response and most also  
335 (12/17) had a negative IgM. This suggests either a false positive anti-S IgG result or early  
336 detection of the seroconversion process in asymptomatic individuals. We have been following  
337 part of this cohort longitudinally and aim to determine if these individuals mount a permanent  
338 immune response over time. Furthermore, a study conducted by Public Health England also

339 independently suggested the same optimized threshold to increase the sensitivity of the assay  
340 (28). Of interest, the same cut-off is currently used in Europe and provides external validation of  
341 our findings. Taken together, our data lend further support for optimizing the assay threshold to  
342 achieve better performance characteristics.

343  
344 These differences between serological assays are also observed between vendors as well. In a  
345 head-to-head comparison of five semi-quantitative SARS-CoV-2 IgG assays found that the  
346 results from assays are not interchangeable despite good correlation to neutralizing antibody for  
347 some of them (10). This has been supported by others (9, 29, 30). Collectively, this highlights  
348 the need for harmonization between all serological assays. This is of paramount importance as  
349 it will enable us to draw meaningful conclusions about correlation of immunity and being better  
350 equipped to overcoming the SARS-CoV-2 pandemic.

351  
352 The present study benefited from a large sample size. Certain limitations are acknowledged.  
353 The gold standard for determining protective antibody is a virus neutralization test which we  
354 were unable to compare to the anti-N & anti-S assay as it requires live pathogen and a biosafety  
355 level 3 laboratory. The study is limited by a cross sectional study design which may under- or  
356 overestimate the seroprevalence. We were unable to correlate days since RT-PCR result or  
357 viral load with quantitative antibody levels and it may provide insight about antibody kinetics  
358 (31). The samples were obtained from a single timepoint preventing characterization of antibody  
359 kinetics on performance characteristics; however, a subset of participants is being prospectively  
360 followed in three-month intervals which will enable future analysis. Lastly, the findings are not  
361 generalizable to the larger community and is limited to hospitals.

362  
363 In conclusion, the Abbott SARS-CoV-2 anti-S IgG assay demonstrate acceptable performance  
364 characteristics. The study highlights the presence of infection among participants with no RT-

365 PCR testing and among those with a negative RT-PCR test. It also highlights the need for  
366 optimizing thresholds of the qualitative SARS-CoV-2 IgG assay for better agreement between  
367 assays by the same vendor. Serological testing can aid in identify a better assessment of the  
368 public health burden.

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390 **Conflicts**

391 Abbott Diagnostics provided the reagents for the SARS-CoV-2 IgG II assays.

392

393 **Acknowledgements**

394 We would like to acknowledge the clinical chemistry, phlebotomy, and central receiving staff in

395 the Department of Laboratory Medicine and Pathology at Boston Medical Center for working

396 with the research team to accomplish this study.

397

398 **Funding**

399 The study was funded, in part, by BMC Development Philanthropy Funds for COVID-19

400 research. Abbott Diagnostics provided the reagents for the SARS-CoV-2 IgG II assays.

401

402

403

404

405

406

407

408

409

410

411

412

413



## 414 References

- 415 1. Symptoms 2020 [Available from: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html)
- 416 [ncov/symptoms-testing/symptoms.html](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html)].
- 417 2. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
- 418 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
- 419 JAMA. 2020;324(8):782-93.
- 420 3. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery, diagnostics
- 421 and drug development. J Hepatol. 2021;74(1):168-84.
- 422 4. National S-C-SAEG. Performance characteristics of five immunoassays for SARS-CoV-2: a
- 423 head-to-head benchmark comparison. Lancet Infect Dis. 2020;20(12):1390-400.
- 424 5. Coste AT, Jatou K, Papadimitriou-Olivgeris M, Greub G, Croxatto A. Comparison of SARS-
- 425 CoV-2 serological tests with different antigen targets. J Clin Virol. 2021;134:104690.
- 426 6. Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, et al.
- 427 Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head
- 428 Comparison of Five Quantitative Assays. Microbiol Spectr. 2021:e0024721.
- 429 7. Van Elslande J, Gruwier L, Godderis L, Vermeersch P. Estimated half-life of SARS-CoV-2
- 430 anti-spike antibodies more than double the half-life of anti-nucleocapsid antibodies in
- 431 healthcare workers. Clin Infect Dis. 2021.
- 432 8. Kataria Y, Cole M, Duffy E, de la Cena K, Schechter-Perkins EM, Bouton TC, et al.
- 433 Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an
- 434 academic medical center in Boston, Massachusetts. Sci Rep. 2021;11(1):9694.
- 435 9. Bradley BT, Bryan A, Fink SL, Goecker EA, Roychoudhury P, Huang ML, et al. Anti-SARS-
- 436 CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with
- 437 Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity. J Clin
- 438 Microbiol. 2021;59(9):e0098921.
- 439 10. Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, et al.
- 440 Anti-Spike protein assays to determine post-vaccination antibody levels: a head-to-head
- 441 comparison of five quantitative assays. medRxiv. 2021:2021.03.05.21252977.
- 442 11. EUA Authorized Serology Test Performance: Food and Drug Administration; 2021
- 443 [Available from: [https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance)
- 444 [emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance)].
- 445 12. Eyre DW, Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. Stringent
- 446 thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections. BMC Infect Dis.
- 447 2021;21(1):187.
- 448 13. Jaaskelainen AJ, Kuivanen S, Kekalainen E, Ahava MJ, Loginov R, Kallio-Kokko H, et al.
- 449 Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin
- 450 Virol. 2020;129:104512.
- 451 14. Laboratories A. AdviseDx SARS-CoV-2 IgG II 2021 [Available from:
- 452 <https://www.fda.gov/media/146371/download>].
- 453 15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
- 454 capture (REDCap)--a metadata-driven methodology and workflow process for providing
- 455 translational research informatics support. J Biomed Inform. 2009;42(2):377-81.

- 456 16. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap  
457 consortium: Building an international community of software platform partners. *J Biomed*  
458 *Inform.* 2019;95:103208.
- 459 17. Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viral load and antibody  
460 response in relation to COVID-19 severity. *J Clin Invest.* 2020;130(10):5235-44.
- 461 18. Ravichandran S, Lee Y, Grubbs G, Coyle EM, Klenow L, Akasaka O, et al. Longitudinal  
462 antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers  
463 associated with disease severity and resolution. *Sci Adv.* 2021;7(10).
- 464 19. Ibarrodo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al.  
465 Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. *N Engl J Med.*  
466 2020;383(11):1085-7.
- 467 20. Self WH, Tenforde MW, Stubblefield WB, Feldstein LR, Steingrub JS, Shapiro NI, et al.  
468 Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital  
469 Network - 13 Academic Medical Centers, April-June 2020. *MMWR Morb Mortal Wkly Rep.*  
470 2020;69(35):1221-6.
- 471 21. Bruno-Murtha LA, Osgood R, Lan FY, Buley J, Nathan N, Weiss M, et al. SARS-CoV-2  
472 antibody seroprevalence after the first wave among workers at a community healthcare system  
473 in the Greater Boston area. *Pathog Glob Health.* 2021:1-4.
- 474 22. Fenwick C, Croxatto A, Coste AT, Pojer F, Andre C, Pellaton C, et al. Changes in SARS-  
475 CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in  
476 Population-Based Seroprevalence Studies. *J Virol.* 2021;95(3).
- 477 23. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of Vaccination on  
478 Household Transmission of SARS-CoV-2 in England. *N Engl J Med.* 2021;385(8):759-60.
- 479 24. Mostaghimi D, Valdez CN, Larson HT, Kalinich CC, Iwasaki A. Prevention of host-to-host  
480 transmission by SARS-CoV-2 vaccines. *Lancet Infect Dis.* 2021.
- 481 25. Po Ying Chia SWXO, Calvin J Chiew, Li Wei Ang, Jean-Marc Chavatte, Tze-Minn Mak, Lin  
482 Cui, Shirin Kalimuddin, Wan Ni Chia, Chee Wah Tan, Louis Yi Ann Chai, Seow Yen Tan, Shuwei  
483 Zheng, Raymond Tzer Pin Lin, Linfa Wang, Yee-Sin Leo, Vernon J Lee, David Chien Lye, Barnaby  
484 Edward Young. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-  
485 breakthrough infections: a multi-center cohort study. *MEDRxiv.* 2021.
- 486 26. Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the  
487 results. *Expert Rev Mol Diagn.* 2020;20(5):453-4.
- 488 27. Kim JY, Ko JH, Kim Y, Kim YJ, Kim JM, Chung YS, et al. Viral Load Kinetics of SARS-CoV-2  
489 Infection in First Two Patients in Korea. *J Korean Med Sci.* 2020;35(7):e86.
- 490 28. Public Health England PD, Nuffield Department of Medicine UoO, Trust OUHNF.  
491 Evaluation of sensitivity and  
492 specificity of four commercially  
493 available SARS-CoV-2 antibody  
494 immunoassays. *Public Health England.* 2020.
- 495 29. Kim Y, Lee JH, Ko GY, Ryu JH, Jang JH, Bae H, et al. Quantitative SARS-CoV-2 Spike  
496 Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a  
497 Surrogate Virus Neutralization Test. *Diagnostics (Basel).* 2021;11(8).

- 498 30. Ekelund O, Ekblom K, Somajo S, Pattison-Granberg J, Olsson K, Petersson A. High-  
499 throughput immunoassays for SARS-CoV-2 - considerable differences in performance when  
500 comparing three methods. *Infect Dis (Lond)*. 2021;53(10):805-10.  
501 31. Kahn R, Kennedy-Shaffer L, Grad YH, Robins JM, Lipsitch M. Potential biases arising from  
502 epidemic dynamics in observational seroprotection studies. *medRxiv*. 2020.  
503

504  
505

506 Legend:

507 **Figure 1** – Linearity of Anti-S IgG

508 **Table 1** – Population Demographics by Anti-S IgG quant

509 **Figure 2** – Anti-S IgG by demographics - a). Age b). Gender c). Race

510 **Table 2** – Anti-S IgG vs. SARS-CoV-2 RT-PCR


511 **Figure 3** – Anti-S IgG distribution by SARS-CoV-2 RT-PCR status

512 **Figure 4** – Anti-S IgG distribution days post SARS-CoV-2 RT-PCR result

513 **Table 3** – Anti-N IgG vs. Anti-S IgG Agreement

514  
515  
516  
517  
518  
519

**Figure 1** – Linearity of Anti-S IgG



520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532

533 **Table 1 – Population Demographics by Anti-S IgG quant**

| Anti-S IgG Status                         |                    |                    |                    |                    |                        |
|---|--------------------|--------------------|--------------------|--------------------|------------------------|
| Variable                                  | Total n (column %) | Positive n (row %) | Negative n (row %) | p-value (All Data) | RR (95% CI) (All Data) |
| <b>Total</b>                              | 1743 (100.00)      | 126 (7.23)         | 1617 (92.77)       |                    |                        |
| <b>Sex</b>                                |                    |                    |                    | 0.31               |                        |
| Female                                    | 1306 (74.93)       | 102 (7.81)         | 1204 (92.19)       |                    | Referent               |
| Male                                      | 431 (24.73)        | 24 (5.57)          | 407 (94.43)        |                    | 0.71 (0.46, 1.10)      |
| Nonbinary/3rd Gender                      | 3 (0.17)           | 0 (0.00)           | 3 (100.00)         |                    | 0.00 (N/A)**           |
| <b>Average Age (years) (SD)</b>           | 41.16 (12.39)      | 41.00 (12.21)      | 41.17 (12.41)      | 0.53               |                        |
| <b>BMI</b>                                |                    |                    |                    | p < 0.001*         |                        |
| Underweight (<18.5 kg/m <sup>2</sup> )    | 34 (1.95)          | 0 (0.00)           | 34 (100.00)        |                    | 0.00 (N/A)**           |
| Normal (18.5-24.9 kg/m <sup>2</sup> )     | 844 (48.42)        | 53 (6.28)          | 791 (93.72)        |                    | Referent               |
| Overweight (25.0-29.9 kg/m <sup>2</sup> ) | 528 (30.29)        | 29 (5.49)          | 499 (94.51)        |                    | 0.87 (0.56, 1.36)      |
| Obese (>29.9 kg/m <sup>2</sup> )          | 335 (19.22)        | 43 (12.84)         | 292 (87.16)        |                    | 2.04 (1.40, 2.99)      |
| <b>Hispanic/LatinX</b>                    |                    |                    |                    | 0.10               |                        |
| Yes                                       | 143 (8.20)         | 15 (10.49)         | 128 (89.51)        |                    | Referent               |
| No  | 1594 (91.45)       | 109 (6.84)         | 1485 (93.16)       |                    | 0.65 (0.39, 1.09)      |
| <b>Race</b>                               |                    |                    |                    | 0.52               |                        |
| White                                     | 1299 (74.53)       | 87 (6.70)          | 1212 (93.30)       |                    | Referent               |
| Asian                                     | 160 (9.18)         | 10 (6.25)          | 150 (93.75)        |                    | 0.93 (0.50, 1.76)      |
| Black                                     | 141 (8.09)         | 13 (9.22)          | 128 (90.78)        |                    | 1.38 (0.79, 2.40)      |
| Native American / Pacific Islander        | 7 (0.40)           | 0 (0.00)           | 7 (100.00)         |                    | 0.00 (N/A)**           |
| Other                                     | 123 (7.06)         | 12 (9.76)          | 111 (90.24)        |                    | 1.46 (0.82, 2.59)      |
| <b>Smoking</b>                            |                    |                    |                    | 0.77               |                        |
| No  | 1671 (95.87)       | 122 (7.30)         | 1549 (92.70)       |                    | Referent               |
| Yes                                       | 46 (2.64)          | 4 (8.70)           | 42 (91.30)         |                    | 1.19 (0.46, 3.09)      |


\* Statistically significant when p-value < 0.05

\*\*N/A: unable to divide by 0

Column percentages may not always add up to 100% due to missing data of <5.0%

534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551

552 **Figure 2** – Anti-S IgG by demographics - a). Age b). Gender c). Race



553  
554  
555


**Table 2** – Anti-S IgG vs. SARS-CoV-2 RT-PCR

|            |   | SARS-CoV-2 RT-PCR |          |      |            |
|------------|---|-------------------|----------|------|------------|
|            |   | Positive          | Negative | IND* | Not Tested |
| Anti-S IgG | + | 75                | 9        | 2    | 40         |
|            | - | 10                | 341      | 4    | 1262       |

\*Indeterminate

556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568


569 **Figure 3** – Anti-S IgG distribution by SARS-CoV-2 RT-PCR status



570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593

594  
595

**Figure 4** – Anti-S IgG distribution days post SARS-CoV-2 RT-PCR result



596  
597

**Table 3** – Anti-N IgG vs. Anti-S IgG Agreement

|            |   | Anti-S IgG |      |
|------------|---|------------|------|
|            |   | +          | -    |
| Anti-N IgG | + | 89         | 6    |
|            | - | 37         | 1611 |

McNemar's Test Statistic with Yates' Continuity Correction: 20.93 P value: <0.0001

|            |   | Anti-S IgG |      |
|------------|---|------------|------|
|            |   | +          | -    |
| Anti-N IgG | + | 109        | 21   |
|            | - | 17         | 1596 |

McNemar's Test Statistic with Yates' Continuity Correction: 0.24 P value: <0.0001

598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613

